This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|August 26, 2022
Watson-Marlow and Franz Ziel GmbH Launch Cellefill
Author(s)BioPharm International Editors
Watson-Marlow and Franz Ziel GmbH have launched a new integrated solution to fast-track cell, gene, and biological therapies.
Advertisement
Flexicon Liquid Filling, part of Watson-Marlow Fluid Technology Solutions (WMFTS) and Franz Ziel GmbH announced the launch of Celefill on August 24, 2022, a turnkey, vial fill/finish system with an integrated barrier solution.
Cellefill integrates the features of Flexicon’s FPC60 aseptic vial filling machine with barrier technologies from Franz Ziel. According to a company press release, it is a good manufacturing practice compliant solution that delivers enhanced levels of process flexibility to accelerate the production of advanced therapy medicinal products including cell, gene, and biological therapies. Cellefill’s process design also includes the use of asepticsu single-use systems and pre-steralized ready-to-use product containers.
“Through process flexibility, Cellefill enables the scale out and process repeatability our customers need to assure product quality at all levels of manufacturing,” said Steve Adams, product manager for Cellefill at WMFTS in the press release. “Providing expert guidance and support through a single point of contact, we are a committed project partner to biopharmaceutical companies at the cutting-edge of personalized medicine.”
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5